Skip to contentB
BioCardia, Inc.
B
BCDABioCardia, Inc. Q2 2022 · 10-Q
Revenue$974.00K$974.00K+1,311.6% vs Q2 2021 Net Income-$2.50M-$2.50MN/M vs Q2 2021 EPS, diluted—
Operating Income-$2,496,000N/M Operating Cash Flowderived-$2,645,000N/M
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
BioCardia, Inc. · CIK 925741 · Engraved from SEC EDGAR
Free Cash Flowderived-$2,670,000N/M Margins · derivedOperating margin-256.3%+4800.3 pt vs Q2 2021
Net margin-256.4%+4797.3 pt vs Q2 2021
ended Jun 30, 2022 · filed Aug 10, 2022 · 41 d after period end